JPMorgan Chase & Co. Buys 5,602 Shares of Ardent Health Partners, LLC (NYSE:ARDT)

JPMorgan Chase & Co. boosted its position in shares of Ardent Health Partners, LLC (NYSE:ARDT) by 66.8% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 13,992 shares of the company’s stock after purchasing an additional 5,602 shares during the quarter. JPMorgan Chase & Co.’s holdings in Ardent Health Partners were worth $239,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. US Bancorp DE purchased a new stake in Ardent Health Partners during the fourth quarter worth $31,000. R Squared Ltd purchased a new stake in shares of Ardent Health Partners during the 4th quarter worth $37,000. New York State Common Retirement Fund bought a new stake in Ardent Health Partners during the fourth quarter valued at about $48,000. Rhumbline Advisers grew its stake in Ardent Health Partners by 23.9% in the fourth quarter. Rhumbline Advisers now owns 16,913 shares of the company’s stock valued at $289,000 after purchasing an additional 3,266 shares during the last quarter. Finally, Barclays PLC bought a new position in Ardent Health Partners in the third quarter worth about $385,000.

Ardent Health Partners Trading Up 4.7 %

Shares of ARDT opened at $13.18 on Friday. Ardent Health Partners, LLC has a 52 week low of $11.31 and a 52 week high of $20.72. The stock’s 50-day moving average price is $13.18 and its 200-day moving average price is $15.13. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.78 and a current ratio of 1.91.

Ardent Health Partners (NYSE:ARDT) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of $0.50 by $0.31. The company had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.48 billion. As a group, equities analysts predict that Ardent Health Partners, LLC will post 1.23 EPS for the current year.

Analyst Ratings Changes

ARDT has been the topic of a number of analyst reports. Mizuho cut their price objective on shares of Ardent Health Partners from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 9th. Truist Financial reduced their price target on Ardent Health Partners from $22.00 to $21.00 and set a “buy” rating on the stock in a research report on Monday, January 6th. Morgan Stanley lowered their price objective on Ardent Health Partners from $23.50 to $22.00 and set an “overweight” rating for the company in a research report on Tuesday, January 21st. Stephens reaffirmed an “overweight” rating and set a $22.00 target price on shares of Ardent Health Partners in a research report on Tuesday, April 1st. Finally, Guggenheim began coverage on Ardent Health Partners in a report on Wednesday, April 9th. They issued a “buy” rating and a $16.00 price target for the company. Two investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, Ardent Health Partners presently has an average rating of “Buy” and a consensus price target of $20.58.

Ardent Health Partners Company Profile

Ardent Health Partners, Inc owns and operates a network of hospitals and clinics that provides a range of healthcare services in the United States. It operates acute care hospitals, including rehabilitation hospitals and surgical hospitals. The company was founded in 2001 and is based in Brentwood, Tennessee.